Resmed has added a chief investor relations officer to its leadership team.
Mick Farrell, Resmed’s chairman and CEO, welcomed Salli Schwartz during the company’s Q3 fiscal year 2025 earnings call on April 23.
“I’m very excited to have Salli join the ResMed team, our newest Resmedian,” Farrell said. “She joined us earlier this week and brings more than two decades of experience across capital markets, health care and technology. We look forward to Salli helping us to take investor relations to the next level here at Resmed, providing clarity, transparency and long-term alignment amongst current and future investors and all of our stakeholders.”
In its April 21 news release, Resmed said Schwartz has served “in a range of finance roles at health tech and financial services organizations.”
Schwartz most recently served as the head of investor relations for Illumina Inc., a biotechnology company based in San Diego, California.
“In that role, she led the company’s investor engagement strategy, representing the company’s response to shareholders’ perspectives on corporate strategy, capital allocation, and financial performance,” the release said. “She was also a member of Illumina’s corporate social responsibility executive steering committee and its transformation office.”
“I am excited to join Resmed at such a pivotal moment in its strategy to make better sleep and breathing health more accessible around the world,” Schwartz said in the announcement. “I look forward to partnering with our leadership team and our shareholders to communicate and advance Resmed’s vision and financial targets.”
“Salli is a seasoned financial leader with a proven track record of driving investor relationships supporting business strategy and capital efficiency,” Farrell said in the announcement. “Her leadership and expertise will be critical as we advance our 2030 strategy to drive shareholder value and empower 500 million people worldwide to achieve their full health potential.”
